Dupixent® (dupilumab) Approved in the U.S. as the First-ever …
WEB9 hours ago · Regeneron and Sanofi are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
FDA greenlights Regeneron’s Dupixent for the treatment of COPD
WEB4 hours ago · With the latest nod from the US Food and Drug Administration (FDA), Regeneron Pharmaceuticals and Sanofi have expanded the US label of Dupixent (dupilumab) to treat chronic obstructive...
Sanofi/Regeneron’s Dupixent set to dominate COPD biologics …
WEB6 hours ago · The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 monoclonal antibody, Dupixent, for the US market.
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB9 hours ago · Dupixent is already a blockbuster therapy for a range of immune-mediated diseases, but the Food and Drug Administration’s approval of the drug for chronic obstructive pulmonary disease greatly...
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB9 hours ago · Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of U.S. indications up to six,...
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
WEB9 hours ago · The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies...
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB23 hours ago · The Food and Drug Administration on Friday approved Regeneron Pharmaceuticals and Sanofi’s inflammatory disease drug Dupixent for a common lung disease. The decision could significantly expand use of what is already one of the industry’s best-selling medicines.
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
WEB23 hours ago · Regeneron and Sanofi on Friday said the green light covers Dupixent as an add-on maintenance treatment in certain adults with uncontrolled chronic obstructive pulmonary disease, or COPD, and...
Press Release: Dupixent approved in the US as the first-ever
WEBSep 27, 2013 · In July 2024, Sanofi and Regeneron announced that the European Medicines Agency approved Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised blood eosinophils.
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve ...
WEBSep 11, 2024 · Dupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease. If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S. and European Union .
- Some results have been removed
Skip to content